Base Year
Historical Year
Forecast Year
The urinary incontinence drugs market size was valued at USD 12028.45 million in 2023, driven by the increasing geriatric population across the 7 major markets. The market size is anticipated to grow at a CAGR of 7% during the forecast period of 2024-2032 to achieve a value of USD 22199 million by 2032.
Urinary incontinence is a medical condition in which the patient suffers from unintentional passing of urine. It is a common problem affecting millions of people around the world. There are several types of urinary incontinence, including stress incontinence – when urine leaks out at times when the patient’s bladder is under pressure; for example, when they cough or laugh.
The urinary incontinence drugs market is witnessing significant developments that are expected to influence market growth positively. For example, Versameb's VMB-100, an investigational drug encoding human insulin-like growth factor-1 (IGF-1), has received FDA acceptance for an investigational new drug (IND) application. This marks a significant step toward addressing stress urinary incontinence (SUI) exclusively in female patients. The initiation of a phase 2A open-label dose ascending study in the first half of 2024 aims to evaluate VMB-100's safety, tolerability, and efficacy in treating moderate SUI.
Additionally, a potential breakthrough in the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI) has emerged with the investigational gene therapy URO-902. Results from a phase 2A trial indicate that single-dose URO-902, administered at 24 mg and 48 mg, exhibited clinically relevant reductions in daily micturitions, urgency episodes, and UUI episodes compared to a placebo. This promising data suggests a novel and effective treatment strategy for women facing these conditions, further expected to support the urinary incontinence drugs market growth.
Furthermore, Alembic Pharmaceuticals has received final approval from the FDA for Fesoterodine Fumarate Extended-Release tablets, designed to treat overactive bladder in adults. The approval positions this medication as therapeutically equivalent to the reference listed drug product Toviaz Extended-Release Tablets by Pfizer Inc. This milestone enhances the available options for managing overactive bladder and contributes to the overall growth of the urinary incontinence drugs market. The collective impact of these developments, encompassing innovative therapies and expanded treatment options, is expected to drive market growth by meeting the evolving needs of patients and offering more effective solutions for urinary incontinence.
Market Breakup by Incontinence Type
Market Breakup by Drug Type
Market Breakup by Distribution Channel
Market Breakup by Region
The market for urinary incontinence treatment drugs is poised for substantial growth, primarily driven by the rising prevalence of urinary incontinence, a condition that is expected to escalate the demand for effective treatment drugs. The increasing geriatric population worldwide is a contributing factor to the growth of the market.
As regulatory bodies continue to grant approvals for new drugs in this category, it is further expected to propel the urinary incontinence drugs market growth. This positive trend can be significantly exhibited by the situation in North America, where the urinary incontinence treatment drugs market is anticipated to witness significant expansion in the near future. Factors contributing to this growth include the high prevalence of orthopedic disorders and dysfunctions, favorable health reimbursement policies, and an increased level of awareness.
Moreover, the increasing incidence of neurological disorders in the region adds another dimension to the market's expansion, boosting the demand for urinary incontinence treatment drugs. With these drivers contributing to the market, the urinary incontinence drugs market is expected to experience sustained growth, meeting the healthcare needs of an expanding patient population and driving innovation in the field.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Please note that this list only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Incontinence Type |
|
| Breakup by Drug Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 12028.45 million in 2023, driven by the increased geriatric patients.
The market is anticipated to grow at a CAGR of 7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 22199 million by 2032.
The rising prevalence of urinary incontinence, coupled with the growing geriatric population, are among the major factors driving the market growth.
The market is driven by continuous drug approvals and research and development for their clinical trials.
The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan.
There are various types of incontinence such as urge incontinence, overflow incontinence, stress incontinence, and mixed incontinence, among other type.
Drugs like anticholinergic, skeletal muscle relaxants, antidepressants, alpha-blockers, and topical estrogens, among others are used to treat this condition.
Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Key players involved in the market are Johnson & Johnson, Pfizer Inc, Astellas Pharma, Allergan, Takeda Pharmaceuticals Company, Merck KGaA., Sanofi S.A., Kissei Pharmaceutical, Kyorin Holding, Urovant Sciences, Cook MyoSite, elicept Therapeutics, and Astellas Pharma.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share